Rate of Adverse Events and Healthcare Costs Associated with the Topical Treatment of Rosacea.

Williamson, Todd; Kamalakar, Rajesh; Ogbonnaya, Augustina; Zagadailov, Erin A; Eaddy, Michael; Kreilick, Charlie

Williamson, Todd; Kamalakar, Rajesh; Ogbonnaya, Augustina; Zagadailov, Erin A; Eaddy, Michael; Kreilick, Charlie.

Afiliação

Williamson T; Vice President, US Medical Affairs, Data Generation & Observational Studies, Bayer HealthCare Pharmaceuticals, Whippany, NJ.
Kamalakar R; Senior Health Outcomes Analyst, Health Economics and Outcomes Research, Bayer HealthCare Pharmaceuticals, at the time of completion of the study.
Ogbonnaya A; Associate Director, Real-World Evidence, Xcenda, Palm Harbor, FL.
Zagadailov EA; Assistant Director, Global Health Economics & Outcomes Research, Xcenda, at the time of completion of the study.
Eaddy M; Vice President, Real-World Evidence, Xcenda.
Kreilick C; Deputy Director, US Data Generation & Observational Studies Data Analytics, Bayer HealthCare Pharmaceuticals.

Am Health Drug Benefits ; 10(3): 113-119, 2017 May.

Article em En | MEDLINE | ID: mdl-28626508

Palavras-chave

adherence; adverse event; azelaic acid; benzoyl peroxide; metronidazole; rosacea; sodium sulfacetamide/sulfur; topical treatment; treatment cost; treatment discontinuation; treatment switch

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation / Observational_studies / Risk_factors_studies Idioma: En Revista: Am Health Drug Benefits Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google